Welcome to our dedicated page for Sionna Therapeutics news (Ticker: SION), a resource for investors and traders seeking the latest updates and insights on Sionna Therapeutics stock.
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis, and its news flow reflects ongoing progress in this specialized area of drug development. Company announcements frequently describe advances in its pipeline of small molecule nucleotide binding domain 1 (NBD1) stabilizers and complementary CFTR modulators designed to improve CFTR protein function.
News items for SION often cover key clinical milestones, such as initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis, and the Phase 1 trial assessing SION-451 in dual combinations with SION-2222 and SION-109 in healthy volunteers. Updates may include information on trial design, target patient populations, measures of CFTR function such as sweat chloride levels, and the rationale for combining NBD1 stabilizers with existing therapies.
Investors and observers can also find press releases on Phase 1 data, including reports that SION-719 and SION-451 were generally well tolerated and exceeded target exposure levels, as well as preclinical findings that NBD1 stabilizers increased the half-life of F508del-CFTR protein to levels seen with wild-type CFTR. Additional news highlights Sionna’s participation in scientific meetings like the North American Cystic Fibrosis Conference and appearances at healthcare and investor conferences.
This SION news page aggregates these disclosures, allowing readers to follow developments in Sionna’s CF-focused programs, track clinical and preclinical data releases, and monitor corporate updates that the company furnishes through press releases and related communications.
Sionna Therapeutics (Nasdaq:SION), a clinical-stage biopharmaceutical company focused on cystic fibrosis, will join the 2026 RBC Capital Markets Global Healthcare Conference.
Management will participate in a fireside chat on May 20, 2026 at 2:05 p.m. ET, with a live webcast and replay available via the company’s investor website.
Sionna Therapeutics (Nasdaq:SION) reported Q1 2026 results and CF pipeline progress. Enrollment in the PreciSION CF Phase 2a trial of SION-719 is complete, and a Phase 1 dual-combination trial of SION-451 is ongoing, with topline data for both expected in summer 2026.
Q1 2026 R&D expenses were $19.0M, G&A expenses $10.6M, and net loss $26.8M. Cash, cash equivalents and marketable securities totaled $289.9M at March 31, 2026, expected to fund operations into 2028.
Sionna Therapeutics (Nasdaq: SION) announced completion of enrollment in the PreciSION CF Phase 2a proof-of-concept trial testing SION-719, a first-in-class NBD1 stabilizer added to Trikafta® in adults homozygous for F508del. Topline data are anticipated in summer 2026.
The randomized, double-blind, placebo-controlled, crossover study will evaluate safety, tolerability, pharmacokinetics, and change in sweat chloride as a measure of CFTR function. The trial enrolled at multiple sites including the CF Foundation Therapeutics Development Network.
Sionna Therapeutics (Nasdaq: SION) said management will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. The meetings provide investor access to management to discuss clinical progress in cystic fibrosis programs and corporate strategy.
Sionna Therapeutics (Nasdaq: SION) reported fourth-quarter and full-year 2025 results and a pipeline update. Cash, cash equivalents and marketable securities totaled $310.3 million as of December 31, 2025, expected to fund operations into 2028.
Ongoing Phase 2a PreciSION CF trial of SION-719 and a Phase 1 dual-combination trial of SION-451 remain on track with topline data anticipated in mid-2026. Company reported higher net loss and increased general and administrative expenses for 2025.
Sionna Therapeutics (Nasdaq: SION) announced management will participate in investor fireside chats in March 2026. Events include TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 2:30 p.m. ET and Leerink Partners Global Healthcare Conference on March 10, 2026 at 1:40 p.m. ET.
Live webcasts and replays will be available in the Investors section at https://investors.sionnatx.com/.
Sionna Therapeutics (Nasdaq: SION) announced management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 2:00 p.m. ET. A live webcast and a replay will be available on Sionna's Investors "Events" page.
The presentation focuses on the company’s clinical-stage programs targeting normalization of CFTR function for cystic fibrosis.
Sionna Therapeutics (Nasdaq: SION) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:45 a.m. PT / 12:45 p.m. ET. The company is a clinical-stage biopharmaceutical focused on developing medicines to normalize CFTR function for cystic fibrosis.
A live webcast of the presentation will be available on the company’s Investors > Events page at https://investors.sionnatx.com/, and a replay will be posted after the event.
Sionna Therapeutics (Nasdaq: SION) announced that management will participate in fireside chats at two investor conferences in early December 2025: the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 12:30 p.m. ET and the Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 9:45 a.m. ET. The company is a clinical-stage biopharmaceutical developer focused on medicines that normalize CFTR function for cystic fibrosis.
Live webcasts will be available on the company’s Investors > Events page at https://investors.sionnatx.com/, and replays will be posted after the events.
Sionna Therapeutics (Nasdaq: SION) reported Q3 2025 results and pipeline progress on Nov 5, 2025. Key updates include initiation of the PreciSION CF Phase 2a trial of SION-719 as an add-on to standard of care and initiation of a Phase 1 dual-combination trial of SION-451; topline data from both trials are anticipated in mid-2026. The FDA cleared an IND for SION-451. Preclinical and Phase 1 data showed NBD1 stabilizers increased F508del-CFTR half-life toward wild-type levels and exceeded target exposures. Financials: cash and equivalents $325.0M expected to fund operations into 2028; Q3 R&D $16.0M, G&A $7.8M, net loss $20.3M.